KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Gains from Sales and Divestitures: 2019-2025

Historic Gains from Sales and Divestitures for TherapeuticsMD (TXMD) over the last 5 years, with Sep 2025 value amounting to $5,000.

  • TherapeuticsMD's Gains from Sales and Divestitures fell 86.84% to $5,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5,000, marking a year-over-year decrease of 86.84%. This contributed to the annual value of $38,000 for FY2024, which is 78.89% down from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's Gains from Sales and Divestitures is $5,000, which was down 0.00% from $5,000 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Gains from Sales and Divestitures registered a high of $2.0 million during Q3 2021, and its lowest value of $7 during Q1 2024.
  • For the 3-year period, TherapeuticsMD's Gains from Sales and Divestitures averaged around $34,376, with its median value being $6,000 (2024).
  • In the last 5 years, TherapeuticsMD's Gains from Sales and Divestitures crashed by 99.68% in 2022 and then spiked by 54,945.87% in 2023.
  • Quarterly analysis of 5 years shows TherapeuticsMD's Gains from Sales and Divestitures stood at $103,000 in 2021, then slumped by 99.68% to $327 in 2022, then surged by 54,945.87% to $180,000 in 2023, then plummeted by 78.89% to $38,000 in 2024, then plummeted by 86.84% to $5,000 in 2025.
  • Its Gains from Sales and Divestitures stands at $5,000 for Q3 2025, versus $5,000 for Q2 2025 and $2,000 for Q1 2025.